Rodabe Amaria

Company: MD Anderson Cancer Center

Job title: PROFESSOR

Bio:

Since joining the Department of Melanoma Medical Oncology at MD Anderson Cancer Center in July 2013, Dr. Amaria has worked to establish herself as a clinical and translational researcher. She has been the Principal Investigator or Co-Principal Investigator of numerous clinical trials including a mix of industry-sponsored trials and investigator-initiated where she had the key role in design and implementation. Dr. Amaria’s research interests have coalesced around three major subjects; neoadjuvant therapy, trials targeting NRAS mutated melanoma and adoptive cell therapy in metastatic melanoma. Dr Amaria leads the MD Anderson Adoptive Cell Therapy with Tumor Infiltrating Lymphocyte (TIL) program and has extensive experience designing and implementing studies using both un-engineered and engineered TIL She is also managing TIL therapy in other solid tumors including various forms of gynecologic, gastrointestinal cancers and sarcomas. Dr. Amaria has been the Director of Clinical Research for the Melanoma Medical Oncology group at MD Anderson since 2022.

Seminars:

Scaling TIL Therapy: Clinical Lessons from the Front Lines 4:00 pm

Managing the operational and logistical hurdles of expanding TIL programs beyond early-phase trials Recognizing patient care complexities and toxicity management challenges in real-world settings Adapting institutional workflows and multidisciplinary coordination to support broader clinical adoptionRead more

day: Conference Day One PM

Panel Discussion: Exploring Real-World Perspectives from Patients & Providers Driving Better TIL Outcomes 4:30 pm

Hearing directly from patients about their experiences with TIL therapy, including the challenges and successes they faced Gaining insights from healthcare providers on the practical aspects of administering TIL therapy and managing patient care Discussing collaborative solutions to improve patient outcomes and enhance the overall TIL therapy experienceRead more

day: Conference Day One PM